poisar

Stocks · News reference

12 Health Care Stocks Moving In Tuesday's Intraday Session

BenzingaBenzinga Insights

Gainers Picard Medical (AMEX:PMI) shares moved upwards by 82.7% to $9.38 during Tuesday's regular session. The market value of their outstanding shares is at $10.5 million. As per the news, the Q2 earnings report

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Source
benzinga
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. Globenewswire IncDelveinsight

    NSCLC Treatment Landscape Shifts as ESMO 2026 Spotlights MET, KRAS, and TROP2 Advances, Says DelveInsight

    The non-small cell lung cancer market is shifting toward precision, biomarker-guided treatment sequencing. ESMO 2026 presented Phase III data showing savolitinib plus osimertinib improved survival in MET-altered EGFR-mutated NSCLC, divarasib outperformed approved KRAS G12C inhibitors, and TROP2-directed ADCs demonstrated durable gains. The 7MM NSCLC market is projected to double from USD 33 billion in 2025 to USD 67 billion by 2036, driven by expanded screening, biomarker-driven therapies, and label expansions into earlier-stage disease.

  2. Globenewswire IncPrecedence Research

    Biotechnology Market Companies 2027 Analysis: Amgen, Gilead, Regeneron, Vertex and Moderna Post Strong 2026 Results as Billion-Dollar Deals Reshape a Market Headed for USD 6.34 Trillion by 2035

    The global biotechnology market, valued at USD 2.02 trillion in 2026, is projected to reach USD 6.34 trillion by 2035 at a 13.61% CAGR. Leading biotech companies including Amgen, Gilead, Regeneron, Vertex, and Moderna reported strong Q3 2026 results with revenue growth ranging from 8% to 36%. The sector experienced record dealmaking activity with major acquisitions totaling tens of billions of dollars, driven by patent expiries, strong cash flows, and strategic pipeline expansion in oncology, immunology, and advanced therapies.

  3. Globenewswire IncNa

    Picard Medical Reports Third Quarter 2026 Financial Results; Gross Profit Positive for Third Consecutive Quarter; Net Loss Narrows 79% to $2.2 Million

    Picard Medical reported Q3 2026 results showing positive gross profit for the third consecutive quarter, with net loss narrowing 79% to $2.2 million. Nine-month revenue increased 10% to $4.3 million with gross profit improving to $1.0 million from a prior-year loss. The company completed repayment of its Senior Secured Note and expects Q4 2026 product sales to exceed prior year, though it faces capital needs and substantial doubt about continuing as a going concern.